As BTL Aesthetics marks its five-year anniversary in Australia, the company has swiftly positioned itself as a pioneer in cutting-edge technologies, earning the loyalty of practitioners and patients alike.
Following the commemoration of 30 years of innovation at the BTL Group last year, the company is heralding another noteworthy milestone: celebrating 5 years since the debut of the first BTL device in Australia.
Since then, BTL has taken Australia and New Zealand by storm and launched multiple first-in-class devices, introduced unique synergistic combination treatments and protocols, and catapulted to the forefront of the minimally invasive aesthetics market.
Further cementing its reputation for innovation, the company recently won the APAC Insider Award for the Most Innovative Aesthetic Solutions Manufacturer.
‘We’re excited to celebrate our 5th anniversary in BTL Australia and New Zealand. Our products are not just an innovation for today; they lay the foundation for future advancements, assuring our partners’ that our technological progress continues to add value for their patients and redefine both their practices and the industry itself,’ says Gareth Pepper, Sales Director of BTL Aesthetics Australia and New Zealand.
BTL’s portfolio includes internationally well-known flagship products EMSCULPT NEO® and EMSELLA®. With 50 peer-reviewed studies*, the proprietary HIFEM® (High-Intensity Focused Electromagnetic) technology used in EMSCULPT® and EMSCULPT NEO, along with its application in EMSELLA® in the intimate health field, has become one of the most intensively researched modalities used in non-invasive body shaping.
EMSELLA® has proven to be a breakthrough treatment for incontinence and intimate health for men and women. In addition to helping patients solve a myriad of intimate health issues, it also elevates practices to another level as it boasts an average ROI of around 6 months.
Last year, the company introduced unique products to Australia and New Zealand in the field of facial aesthetics, namely EMFACE® and EXION™.
The launch of EMFACE® was highly anticipated, thanks to its innovative approach to facial rejuvenation and use of technology. The device uses two synchronised energies that simultaneously affect facial skin and muscles, resulting in skin recontouring and lifting, skin tone refreshment, and the smoothing of lines and wrinkles.
With its newest Submentum applicator – introduced in January 2024 in the United States and launched in Australia in March 2024 – EMFACE® can now also target double chins, an innovation that has tripled the device’s utilisation globally.
The latest product brought to Australia and New Zealand is EXION™. This versatile 3-in-1 multi-platform has been described as the future of aesthetics. It addresses multiple face and body concerns, offering solutions for skin tightening, texture improvement and fibrotic tissue correction in over 20 body areas with unprecedented results. The ground-breaking feature of EXION™ is the fractional RF applicator powered by AI, specifically designed to revolutionise the traditional concept of painful microneedling and deliver exceptional results to patients in a more comfortable manner.
A key ingredient to BTL’s success is that all products are developed in-house, backed by solid science, and manufactured by BTL.
The company offers a golden business opportunity for partner clinics, providing extensive training and after-sales support as well as trusted, reliable and cutting-edge technologies.
For more information about BTL products, contact BTL Aesthetics on 0435 769 639, email sales@btlmed.com.au or visit btlaesthetics.com.au
*Data on file
